GSK Provides Update on Latozinemab Clinical Trial Results

GSK plc and Alector, Inc. announced the headline results from the INFRONT-3 clinical trial evaluating latozinemab for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN). While latozinemab showed a statistically significant effect on the biomarker co-primary endpoint of plasma progranulin concentrations, it did not demonstrate benefit on the clinical co-primary endpoint of slowing FTD-GRN progression. Secondary and exploratory endpoints also did not show treatment-related effects. Preliminary safety data did not highlight major concerns, but further analysis is ongoing. As a result, the open-label extension portion of the INFRONT-3 trial and the continuation study for latozinemab will be discontinued. GSK will evaluate the data to inform future research in neurodegeneration. The full results will be presented at an upcoming medical congress.